The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
Open accessAbstract
Pancreatic cancer is a disease that has a very high fatality rate and one of the highest mortality ratios among all major cancers, remaining the fourth leading cause of cancer-related deaths in developed countries. The major treatment of pancreatic cancer is surgery; however, only 15–20% of patients are candidates for it at the diagnosis of disease. On the other hand, survival in patients, who undergo surgery, is less than 30%. In most cancers, genome stability is disturbed and pancreatic cancer is not the exception. Approximately 97% of pancreatic cancers have gene derangements, defined by point mutations, amplifications, deletions, translocations, and inversions. This review describes the most frequent genetic alterations found in pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Xiang, J.-F., Wang, W.-Q., Liu, L., Xu, H., Wu, C., Yang, J., Qi, Z.-H., Wang, Y.-Q., Xu, J., Liu, C., et al. (2016) · Scientific Reports · doi:10.1038/srep19222 · Cited by 34
RetractedRahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website
Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., Flanagan, A., Teague, J., Futreal, P. A., Stratton, M. R., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601894 · Cited by 1,267
Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., & Kern, S. E. (1994) · Nature Genetics · doi:10.1038/ng0994-27 · Cited by 1,136
Germline p16 mutations in familial melanoma
Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A., & Dracopoli, N. C. (1994) · Nature Genetics · doi:10.1038/ng0994-15 · Cited by 977
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.
Schutte, M. E. M., Hruban, R. H., Geradts, J., Maynard, R. D., Hilgers, W., Rabindran, S. K., Moskaluk, C. A., Hahn, S. A., Schwarte‐Waldhoff, I., Schmiegel, W., et al. (1997) · PubMed · Cited by 659
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer
Welcsh, P. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.705 · Cited by 648 · cited 1×
“Mutated and thus frequently inactivated BRCA2 cause an increased risk of developing breast, ovarian, prostate, stomach, and pancreatic familial cancers [46,47].”
BackgroundGermline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.
Goggins, M., Schutte, M. E. M., Lü, J., Moskaluk, C. A., Weinstein, C. L., Petersen, G. M., Yeo, C. J., Jackson, C. E., Lynch, H. T., Hruban, R. H., et al. (1996) · PubMed · Cited by 642
KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas
Smit, V. T. H. B. M., Boot, A. J. M., Smits, A. M. M., Fleuren, G. J., Cornelisse, C. J., & Bos, J. L. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.16.7773 · Cited by 626
Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation.
Marais, R., Light, Y., Paterson, H. F., & Marshall, C. J. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07316.x · Cited by 612
Redston, M. S., Caldas, C., Seymour, A. B., Hruban, R. H., da Costa, L., Yeo, C. J., & Kern, S. E. (1994) · PubMed · Cited by 451
Next-generation sequencing for cancer diagnostics: a practical perspective.
Meldrum, C. J., Doyle, M., & Tothill, R. W. (2011) · Europe PMC (PubMed Central) · Cited by 443
SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer
Blackford, A., Serrano, O. K., Wolfgang, C. L., Parmigiani, G., Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Eshleman, J. R., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0227 · Cited by 371
Vasen, H. F. A., Gruis, N. A., Frants, R. R., van der Velden, P. A., Hille, E. T. M., & Bergman, W. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000915)87:6<809::aid-ijc8>3.0.co;2-u · Cited by 347
Golan, T., Khvalevsky, E. Z., Hubert, A., Gabai, R. M., Hen, N., Segal, A., Domb, A., Harari, G., David, E. B., Raskin, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4183 · Cited by 336 · cited 1×
“Phase I/II study using siRNA against G12D in combination with chemotherapy was performed in 15 locally advanced pancreatic cancer patients [18].”
MethodCarrato, A., Falcone, A., Ducreux, M., Valle, J. W., Parnaby, A., Djazouli, K., Alnwick-Allu, K., Hutchings, A., Palaska, C., & Parthenaki, I. (2015) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-015-9724-1 · Cited by 270
BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) Mutations in Distinct Subsets of Pancreatic Cancer
Calhoun, E. S., Jones, J. B., Ashfaq, R., Adsay, V., Baker, S. J., Valentine, V., Hempen, P. M., Hilgers, W., Yeo, C. J., Hruban, R. H., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63485-2 · Cited by 232
BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian.
Friedenson, B. (2005) · PubMed Central · Cited by 218
Cell cycle arrest and DNA endoreduplication following p21Waf1/Cip1 expression
Bates, S., Ryan, K. M., Phillips, A. C., & Vousden, K. H. (1998) · Oncogene · doi:10.1038/sj.onc.1202104 · Cited by 176
Roles of BRCA1 in DNA damage repair: a link between development and cancer
Deng, C.-X. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg082 · Cited by 168
KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma
Cicenas, J., Tamošaitis, L., Kvederavičiūtė, K., Tarvydas, R., Staniute, G., Kalyan, K. P., Meškinytė-Kaušilienė, E., Stankevičius, V., & Valius, M. (2017) · Medical Oncology · doi:10.1007/s12032-016-0879-9 · Cited by 159
Self-citationKim, S. T., Lim, D. H., Jang, K.-T., Lim, T., Lee, J., Choi, Y.-L., Jang, H.-L., Yi, J. H., Baek, K. K., Park, S. H., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0269 · Cited by 145
Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation
Gallo, A., Cuozzo, C., Esposito, I., Maggiolini, M., Bonofiglio, D., Vivacqua, A., Garramone, M., Weiß, C., Bohmann, D., & Musti, A. M. (2002) · Oncogene · doi:10.1038/sj.onc.1205822 · Cited by 113
Levy-Strumpf, N., Yonish-Rouach, E., Oren, M., & Kimchi, A. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.12.7942-7952.1993 · Cited by 102
Stadler, Z. K., Salo‐Mullen, E. E., Patil, S. M., Pietanza, M. C., Vijai, J., Saloustros, E. S., Hansen, N. A. L., Kauff, N. D., Kurtz, R. C., Kelsen, D. P., et al. (2011) · Cancer · doi:10.1002/cncr.26191 · Cited by 98
Loss of Smad4 Function in Pancreatic Tumors
Maurice, D., Pierreux, C. E., Howell, M. T., Wilentz, R. E., Owen, M. J., & Hill, C. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105895200 · Cited by 94
Dpc4 transcriptional activation and dysfunction in cancer cells.
Dai, J. L., Turnacioglu, K. K., Schutte, M. E. M., Sugar, A. Y., & Kern, S. E. (1998) · PubMed · Cited by 90
Hayashi, H., Kohno, T., Ueno, H., Hiraoka, N., Kondo, S., Saito, M., Shimada, Y., Ichikawa, H., Kato, M., Shibata, T., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000760 · Cited by 88
Bosscher, K. D., Hill, C., & Nicolás, F. J. (2004) · Biochemical Journal · doi:10.1042/bj20031886 · Cited by 81
BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts
Lohse, I., Borgida, A., Cao, P., Cheung, M., Pintilie, M., Bianco, T., Hölter, S. M., Ibrahimov, E., Kumareswaran, R., Bristow, R. G., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.220 · Cited by 79
Boeck, S., Jung, A., Laubender, R. P., Neumann, J., Egg, R., Goritschan, C., Ormanns, S., Haas, M., Modest, D. P., Kirchner, T., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0767-4 · Cited by 77
Hwang, R. F., Gordon, E. M., Anderson, W. F., & Parekh, D. (1998) · Surgery · doi:10.1016/s0039-6060(98)70114-x · Cited by 69
Sonnenblick, A., Kadouri, L., Appelbaum, L., Peretz, T., Sagi, M., Goldberg, Y., & Hubert, A. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.3.16292 · Cited by 65
Chen, J., Li, D., Killary, A. M., Sen, S., Amos, C. I., Evans, D. B., Abbruzzese, J. L., & Frazier, M. L. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0220-8 · Cited by 61
Singh, P., Srinivasan, R., & Wig, J. D. (2012) · Pancreas · doi:10.1097/mpa.0b013e318247d6af · Cited by 54
Boulton, S. J. (2006) · Cell Cycle · doi:10.4161/cc.5.14.2930 · Cited by 52
James, E. S., Waldron-Lynch, M., & Saif, M. W. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32832b511e · Cited by 46
Grochola, L. F., Taubert, H. W., Greither, T., Bhanot, U. K., Udelnow, A., & Würl, P. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181f95104 · Cited by 35
Ormanns, S., Siveke, J. T., Heinemann, V., Haas, M., Sipos, B., Schlitter, A. M., Esposito, I., Jung, A., Laubender, R. P., Krüger, S., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-624 · Cited by 34
Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer
Carnevale, J. C., & Ashworth, A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6961 · Cited by 32
Ghiorzo, P., Gargiulo, S., Nasti, S., Pastorino, L., Battistuzzi, L., Bruno, W., Bonelli, L. A., Taveggia, P., Pugliese, V., Borgonovo, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5624 · Cited by 29
Huang, L., Wu, C. H., Yu, D., Wang, C., Che, X., Miao, X., Zhai, K., Chang, J., Jiang, G., Yang, X., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt004 · Cited by 24
BRCA2: breaks, mistakes and failed separations
Rudkin, T. M., & Foulkes, W. D. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.02.003 · Cited by 21
Luo, Y., Tian, L., Ye, F., Miaoying, Y., Chen, X., & Huang, Q. (2012) · Pathology & Oncology Research · doi:10.1007/s12253-012-9555-3 · Cited by 17
Cao, D., Ashfaq, R., Goggins, M., Hruban, R. H., Kern, S. E., & Iacobuzio–Donahue, C. A. (2008) · PubMed Central · Cited by 15
Xiang, J., Wang, W., Liu, L., Xu, H.-X., Wu, C., Yang, J., Qi, Z., Wang, Y., Xu, J., Liu, C., et al. (2016) · Scientific Reports · doi:10.1038/srep25115 · Cited by 5
Cited by
G-quadruplexes: a promising target for cancer therapy
Kosiol, N., Juranek, S., Brossart, P., Heine, A., & Paeschke, K. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01328-4 · Cited by 533
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment
Zhao, Z., & Liu, W. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820962117 · Cited by 348
Gu, Y., Ji, Y., Jiang, H., & Qiu, G. (2020) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2020.0078 · Cited by 28
“Furthermore, some studies identified that mutated P53 associated with poor prognosis in pancreatic cancer, but inconsistent results were reached (Cicenas et al. , 2017).”
InfluentialA novel tp53-associated nomogram to predict the overall survival in patients with pancreatic cancer
Liu, X., Chen, B., Chen, J., & Sun, S. (2021) · BMC Cancer · doi:10.1186/s12885-021-08066-2 · Cited by 24
Metadata
- Authors
- Cicenas, J., Kvederaviciute, K., Meskinyte, I., Meskinyte-Kausiliene, E., Skeberdyte, A., & Cicenas, J.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2017-04-28
- Volume
- 9
- Issue
- 5
- Pages
- 42
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2608139406
- Cited by
- 272
- References
- 47
- FWCI
- 9.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.